| Literature DB >> 22365521 |
Zubin M Bamboat1, Ronald P Dematteo.
Abstract
Despite being the most common sarcoma of the gastrointestinal tract, gastrointestinal stromal tumor (GIST) has been widely recognized as a unique entity for just over a decade. The advent of tyrosine kinase inhibitors has revolutionized the diagnosis and treatment of GIST. Although surgery remains the only chance for cure, multimodal treatment that includes molecular therapy continues to develop. Optimal management of GIST requires careful radiographic, pathologic, medical, and surgical care, emphasizing the need for a multidisciplinary approach. This review highlights recent developments in the management of GIST. Copyright ÂEntities:
Mesh：
Substances：
Year: 2012 PMID： 22365521 PMCID： PMC3386646 DOI： 10.1016/j.soc.2011.12.004
Source DB: PubMed Journal: Surg Oncol Clin N Am ISSN： 1055-3207 Impact factor: 3.495